225 related articles for article (PubMed ID: 14695825)
61. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
[TBL] [Abstract][Full Text] [Related]
62. Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.
Björklund C; Adolfsson H; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2010 Feb; 18(4):1711-23. PubMed ID: 20122837
[TBL] [Abstract][Full Text] [Related]
63. De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II.
Carcache DA; Hörtner SR; Bertogg A; Binkert C; Bur D; Märki HP; Dorn A; Diederich F
Chembiochem; 2002 Nov; 3(11):1137-41. PubMed ID: 12404641
[No Abstract] [Full Text] [Related]
64. The protonation state of the catalytic aspartates in plasmepsin II.
Friedman R; Caflisch A
FEBS Lett; 2007 Aug; 581(21):4120-4. PubMed ID: 17689534
[TBL] [Abstract][Full Text] [Related]
65. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring.
Friedman R; Caflisch A
ChemMedChem; 2009 Aug; 4(8):1317-26. PubMed ID: 19472268
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D.
Carroll CD; Johnson TO; Tao S; Lauri G; Orlowski M; Gluzman IY; Goldberg DE; Dolle RE
Bioorg Med Chem Lett; 1998 Nov; 8(22):3203-6. PubMed ID: 9873703
[TBL] [Abstract][Full Text] [Related]
67. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
[TBL] [Abstract][Full Text] [Related]
68. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
69. Characterisation of Plasmodium falciparum aspartic protease inhibition by piperidine derivatives.
Saify ZS; Nisa M; Azhar KF; Azim MK; Rasheed H; Mushtaq N; Arain MA; Haider S; Khanum M; Ahmed W
Nat Prod Res; 2011 Dec; 25(20):1965-8. PubMed ID: 22050275
[TBL] [Abstract][Full Text] [Related]
70. Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank.
Robbins AH; Dunn BM; Agbandje-McKenna M; McKenna R
Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):294-6. PubMed ID: 19237752
[TBL] [Abstract][Full Text] [Related]
71. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
Andrews KT; Fairlie DP; Madala PK; Ray J; Wyatt DM; Hilton PM; Melville LA; Beattie L; Gardiner DL; Reid RC; Stoermer MJ; Skinner-Adams T; Berry C; McCarthy JS
Antimicrob Agents Chemother; 2006 Feb; 50(2):639-48. PubMed ID: 16436721
[TBL] [Abstract][Full Text] [Related]
72. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
73. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
[TBL] [Abstract][Full Text] [Related]
74. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
[TBL] [Abstract][Full Text] [Related]
75. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
Sealy JM; Truong AP; Tso L; Probst GD; Aquino J; Hom RK; Jagodzinska BM; Dressen D; Wone DW; Brogley L; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Dappen MS; Toth G; Pan H; Ruslim L; Miller J; Bova MP; Sinha S; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2009 Nov; 19(22):6386-91. PubMed ID: 19811916
[TBL] [Abstract][Full Text] [Related]
76. In vitro and in silico studies of naphthoquinones and peptidomimetics toward Plasmodium falciparum plasmepsin V.
Sittikul P; Songtawee N; Kongkathip N; Boonyalai N
Biochimie; 2018 Sep; 152():159-173. PubMed ID: 30103899
[TBL] [Abstract][Full Text] [Related]
77. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
Miura T; Hidaka K; Uemura T; Kashimoto K; Hori Y; Kawasaki Y; Ruben AJ; Freire E; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2010 Aug; 20(16):4836-9. PubMed ID: 20634066
[TBL] [Abstract][Full Text] [Related]
78. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
[TBL] [Abstract][Full Text] [Related]
79. Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic.
Kim YM; Lee MH; Piao TG; Lee JW; Kim JH; Lee S; Choi KM; Jiang JH; Kim TU; Park H
J Biochem; 2006 Feb; 139(2):189-95. PubMed ID: 16452306
[TBL] [Abstract][Full Text] [Related]
80. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.
Majer P; Collins JR; Gulnik SV; Erickson JW
Protein Sci; 1997 Jul; 6(7):1458-66. PubMed ID: 9232647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
